<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432027</url>
  </required_header>
  <id_info>
    <org_study_id>PRI-C-82T-2101</org_study_id>
    <nct_id>NCT02432027</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test</brief_title>
  <official_title>A Single-Center, Randomized, Observer Blind, Vehicle- and Comparator-controlled Trial to Evaluate the Antipsoriatic Efficacy and Safety of Topical Formulations of C-82 in a Psoriasis Plaque Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prism Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prism Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of topical C-82 in a psoriasis plaque test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to evaluate antipsoriatic efficacy of the C-82 topical
      gel compared with vehicle by measurement of the thickness of the Echo Lucent Band (ELB) of
      the psoriatic infiltrate using 20 MHz sonography. To gain additional information about
      possible efficacy the change of the test fields compared to untreated plaque will be
      clinically assessed by visual scoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antipsoriatic efficacy of the C-82 topical gel compared with vehicle by measurement of the thickness of the Echo Lucent Band (ELB) of the psoriatic infiltrate</measure>
    <time_frame>day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>antipsoriatic efficacy compared to control by clinical assessment using a 5-point score.</measure>
    <time_frame>Day 8 &amp; Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with adverse events</measure>
    <time_frame>daily through Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>IMP 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C-82 Topical Gel, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMP 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>C-82 Topical Gel, placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMP 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daivonex cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMP 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diprosis gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-82 Topical Gel, Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>IMP 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-82 Topical Gel, 1%</intervention_name>
    <description>active</description>
    <arm_group_label>IMP 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivonex cream</intervention_name>
    <description>comparator</description>
    <arm_group_label>IMP 3</arm_group_label>
    <other_name>calcipotriol 50mcg/g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprosis gel</intervention_name>
    <description>comparator</description>
    <arm_group_label>IMP 4</arm_group_label>
    <other_name>betamethasone, 0.5 mg/g</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate chronic stable plaque type psoriasis

          -  plaques thickness of at least 200 Âµm

          -  lesion(s) on the trunk or extremities (excluding palms/soles)

          -  skin must be without disease findings

        Exclusion Criteria:

          -  other skin disease

          -  psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, psoriasis
             arthropathica and pustular psoriasis

          -  treatment with any locally acting medications (including anti-psoriatics like vitamin
             D analogues, dithranol) within 2 weeks preceding and during the trial

          -  treatment with any systemic medications (including anti-psoriatics like
             corticosteroids, cytostatics or retinoids) or medications which are known to provoke
             or aggravate psoriasis (e.g. beta-blocker, anti-malarial drugs, lithium) or
             phototherapy/PUVA within 4 weeks preceding and during the trial

          -  treatment with any biologics within 3 months preceding and during the trial

          -  known allergic reactions, irritations or sensitivity to the active ingredients or
             other components of the investigational products (e.g. Carbomere 940, propylene
             glycol)

          -  drug or alcohol abuse

          -  symptoms of a clinically significant illness within 4 preceding and during the trial

          -  participation another clinical trial within 4 weeks of this clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Theis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinische Forschung Schwerin GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

